CompletedNot applicableNCT04602026

The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer

Studying NON RARE IN EUROPE: Adenocarcinoma of stomach

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ohio State University Comprehensive Cancer Center
Principal Investigator
Mark Rubinstein, PhD
Ohio State University Comprehensive Cancer Center
Intervention
Best Practice(other)
Enrollment
66 enrolled
Eligibility
18 years · All sexes
Timeline
20202024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04602026 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

← Back to all trials